203 related articles for article (PubMed ID: 25597616)
1. Decrease of LL-37 in systemic sclerosis: a new marker for interstitial lung disease?
Hizal M; Bruni C; Romano E; Mazzotta C; Guiducci S; Bellando Randone S; Blagojevic J; Lepri G; Tufan A; Matucci Cerinic M
Clin Rheumatol; 2015 Apr; 34(4):795-8. PubMed ID: 25597616
[TBL] [Abstract][Full Text] [Related]
2. Association of elevated α-defensin levels with interstitial pneumonia in patients with systemic sclerosis.
Sakamoto N; Kakugawa T; Hara A; Nakashima S; Yura H; Harada T; Ishimoto H; Yatera K; Kuwatsuka Y; Hara T; Ichinose K; Obase Y; Ishimatsu Y; Kohno S; Mukae H
Respir Res; 2015 Dec; 16():148. PubMed ID: 26654954
[TBL] [Abstract][Full Text] [Related]
3. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
4. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
[TBL] [Abstract][Full Text] [Related]
5. A circulating cell population showing both M1 and M2 monocyte/macrophage surface markers characterizes systemic sclerosis patients with lung involvement.
Trombetta AC; Soldano S; Contini P; Tomatis V; Ruaro B; Paolino S; Brizzolara R; Montagna P; Sulli A; Pizzorni C; Smith V; Cutolo M
Respir Res; 2018 Sep; 19(1):186. PubMed ID: 30249259
[TBL] [Abstract][Full Text] [Related]
6. Interleukin-17 and interleukin-23: importance in the pathogenesis of lung impairment in patients with systemic sclerosis.
Olewicz-Gawlik A; Danczak-Pazdrowska A; Kuznar-Kaminska B; Gornowicz-Porowska J; Katulska K; Trzybulska D; Batura-Gabryel H; Silny W; Poplawski D; Hrycaj P
Int J Rheum Dis; 2014 Jul; 17(6):664-70. PubMed ID: 24467649
[TBL] [Abstract][Full Text] [Related]
7. A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis.
Takahashi T; Asano Y; Nakamura K; Yamashita T; Saigusa R; Ichimura Y; Toyama T; Taniguchi T; Yoshizaki A; Tamaki Z; Tada Y; Sugaya M; Kadono T; Sato S
Br J Dermatol; 2016 Dec; 175(6):1195-1203. PubMed ID: 27105895
[TBL] [Abstract][Full Text] [Related]
8. Biomarkers to identify ILD and predict lung function decline in scleroderma lung disease or idiopathic pulmonary fibrosis.
Kennedy B; Branagan P; Moloney F; Haroon M; O'Connell OJ; O'Connor TM; O'Regan K; Harney S; Henry MT
Sarcoidosis Vasc Diffuse Lung Dis; 2015 Sep; 32(3):228-36. PubMed ID: 26422568
[TBL] [Abstract][Full Text] [Related]
9. Serum interleukin-34 levels in patients with systemic sclerosis: Clinical association with interstitial lung disease.
Kuzumi A; Yoshizaki A; Toyama S; Fukasawa T; Ebata S; Nakamura K; Yamashita T; Saigusa R; Miura S; Hirabayashi M; Yoshizaki A; Asano Y; Sato S
J Dermatol; 2018 Oct; 45(10):1216-1220. PubMed ID: 30004593
[TBL] [Abstract][Full Text] [Related]
10. Serum concentration of surfactant protein D in patients with systemic sclerosis: The potential marker of the interstitial lung disease severity.
Grosicka A; Manasar A; Kucharz EJ; Kotyla PJ
Best Pract Res Clin Rheumatol; 2018 Aug; 32(4):541-549. PubMed ID: 31174823
[TBL] [Abstract][Full Text] [Related]
11. A new nucleosomic-based model to identify and diagnose SSc-ILD.
Guiot J; Henket M; Andre B; Herzog M; Hardat N; Njock MS; Moermans C; Malaise M; Louis R
Clin Epigenetics; 2020 Aug; 12(1):124. PubMed ID: 32807242
[TBL] [Abstract][Full Text] [Related]
12. Procollagen Type I and III Aminoterminal Propeptide Levels and Severity of Interstitial Lung Disease in Mexican Women With Progressive Systemic Sclerosis.
Gonzalez-Lopez L; Rocha-Muñoz AD; Olivas-Flores EM; Garcia-Gonzalez A; Peguero-Gómez AR; Flores-Navarro J; Villa-Manzano AI; Zavaleta-Muñiz SA; Salazar-Paramo M; Mejía M; Juárez-Contreras P; Vazquez-Del Mercado M; Cardona-Muñoz EG; Trujillo-Hernández B; Nava-Zavala AH; Gamez-Nava JI
Arch Bronconeumol; 2015 Sep; 51(9):440-8. PubMed ID: 25301411
[TBL] [Abstract][Full Text] [Related]
13. Integrative analysis of lung molecular signatures reveals key drivers of systemic sclerosis-associated interstitial lung disease.
Jung SM; Park KS; Kim KJ
Ann Rheum Dis; 2022 Jan; 81(1):108-116. PubMed ID: 34380701
[TBL] [Abstract][Full Text] [Related]
14. Decreased sputum caveolin-1 is associated with systemic sclerosis related lung disease.
Yilmaz N; Olgun S; Ahiskali R; Karakurt S; Yavuz S
Sarcoidosis Vasc Diffuse Lung Dis; 2014 Apr; 31(1):55-61. PubMed ID: 24751454
[TBL] [Abstract][Full Text] [Related]
15. Circulating monocytes from systemic sclerosis patients with interstitial lung disease show an enhanced profibrotic phenotype.
Mathai SK; Gulati M; Peng X; Russell TR; Shaw AC; Rubinowitz AN; Murray LA; Siner JM; Antin-Ozerkis DE; Montgomery RR; Reilkoff RA; Bucala RJ; Herzog EL
Lab Invest; 2010 Jun; 90(6):812-23. PubMed ID: 20404807
[TBL] [Abstract][Full Text] [Related]
16. Serum metabolites as biomarkers in systemic sclerosis-associated interstitial lung disease.
Meier C; Freiburghaus K; Bovet C; Schniering J; Allanore Y; Distler O; Nakas C; Maurer B
Sci Rep; 2020 Dec; 10(1):21912. PubMed ID: 33318574
[TBL] [Abstract][Full Text] [Related]
17. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
[TBL] [Abstract][Full Text] [Related]
18. High serum C-X-C motif chemokine ligand 10 (CXCL10) levels may be associated with new onset interstitial lung disease in patients with systemic sclerosis: evidence from observational, clinical, transcriptomic and in vitro studies.
Al-Adwi Y; Atzeni IM; Doornbos-van der Meer B; van der Leij MJ; Varkevisser RDM; Kroesen BJ; Stel A; Timens W; Gan CT; van Goor H; Westra J; Mulder DJ
EBioMedicine; 2023 Dec; 98():104883. PubMed ID: 37995465
[TBL] [Abstract][Full Text] [Related]
19. Tumour-associated antigens in systemic sclerosis patients with interstitial lung disease: association with lung involvement and cancer risk.
De Luca G; Bosello SL; Berardi G; Rucco M; Canestrari G; Correra M; Mirone L; Forni F; Di Mario C; Danza FM; Pirronti T; Ferraccioli G
Rheumatology (Oxford); 2015 Nov; 54(11):1991-9. PubMed ID: 26106211
[TBL] [Abstract][Full Text] [Related]
20. Platelet-to-lymphocyte ratio and neutrophil-to-lymphocyte ratio as potential makers for digital ulcers and interstitial lung disease in patients with systemic sclerosis: cross-sectional analysis of data from a prospective cohort study.
Kim A; Kim Y; Kim GT; Ahn E; So MW; Sohn DH; Lee SG
Rheumatol Int; 2020 Jul; 40(7):1071-1079. PubMed ID: 32424613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
